Thrombin mediates the extraintestinal thrombosis associated with experimental colitis.
Recent evidence implicating tissue factor and the protein C pathway in the hypercoagulable state associated with intestinal inflammation suggests that thrombin is likely to contribute to this response. The objective of this study was to assess the role of thrombin in the extraintestinal thrombosis associated with experimental colitis. Thrombus formation was quantified in microvessels of the cremaster muscle in mice with dextran sodium sulfate (DSS)-induced colonic inflammation. The light/dye endothelial injury model was used to elicit thrombus formation in DSS colitic mice treated with either hirudin, heparin, or antithrombin III. The initiation and propagation/stabilization phases of thrombus formation were quantified using the time of onset of the thrombus and time to blood flow cessation, respectively. Thrombus formation was accelerated in arterioles of DSS colitic mice, as exhibited by significant reductions in the time of thrombus initiation and propagation/stabilization. Colitic mice treated with hirudin, heparin, or antithrombin III did not exhibit a significant change in the time of onset of the thrombus compared with untreated colitic mice. However, all three antithrombin agents largely prevented the DSS-induced reduction in the time to flow cessation following light/dye injury, with hirudin offering complete protection. These findings indicate that thrombin plays a major role in the extraintestinal thrombus formation associated with experimental colitis. Thrombin appears to contribute to the propagation/stabilization, rather than initiation, phase of the colitis-associated thrombogenesis at the distant vascular site. The results support the therapeutic use of antithrombin agents for reducing the risk of thromboembolism in patients with inflammatory bowel disease.
Yoshida
Hideo
H
Dept. of Molecular and Cellular Physiology, LSU Health Sciences Ctr., Shreveport, LA 71130-33932, USA.
Russell
Janice
J
Granger
D Neil
DN
D000818:Animals; D001160:Arterioles / Q000502:physiology; D003092:Colitis / Q000139:chemically induced* / Q000378:metabolism*; D016264:Dextran Sulfate / Q000633:toxicity; D006493:Heparin / Q000494:pharmacology; D006629:Hirudins / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018482:Muscle, Skeletal / Q000473:pathology; D013917:Thrombin / Q000378:metabolism*; D013927:Thrombosis / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D014699:Venules / Q000502:physiology
D006629:Hirudins; D006493:Heparin; D016264:Dextran Sulfate; D013917:Thrombin
Thromb Haemost. 2001 Mar;85(3):430-4
11307809
Dig Dis Sci. 2004 Apr;49(4):556-64
15185857
Semin Thromb Hemost. 2002 Oct;28(5):405-14
12420235
Am J Physiol Gastrointest Liver Physiol. 2003 Jan;284(1):G123-9
12388188
Br J Haematol. 2005 Nov;131(4):417-30
16281932
J Thromb Haemost. 2006 Oct;4(10):2230-7
16824188
Ann N Y Acad Sci. 2005 Jun;1051:166-73
16126956
Am J Gastroenterol. 2001 Feb;96(2):487-93
11232695
Inflamm Res. 2002 Apr;51(4):182-7
12058955
Thromb Res. 2004;114(5-6):321-7
15507261
Microcirculation. 2004 Apr-May;11(3):239-47
15280078
QJM. 1997 Mar;90(3):183-8
9093595
Semin Thromb Hemost. 2006 Apr;32 Suppl 1:49-60
16673266
Clin Gastroenterol Hepatol. 2005 Jul;3(7):617-28
16206491
Dig Dis Sci. 2008 Dec;53(12):3170-5
18465235
Thromb Haemost. 2006 Sep;96(3):371-7
16953281
Microcirculation. 2005 Apr-May;12(3):259-74
15814435
Gut. 2004 Apr;53(4):542-8
15016749
J Exp Med. 2007 Jul 9;204(7):1595-601
17562818
J Thromb Haemost. 2003 Jul;1(7):1343-8
12871267
Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1687-93
17556654
Inflamm Bowel Dis. 2007 Jun;13(6):753-8
17260365
Thromb Res. 2007;121(2):241-8
17512574
Circ Res. 2001 Mar 16;88(5):499-505
11249873
J Clin Invest. 2007 Jul;117(7):1951-60
17557119
Nature. 1999 Apr 1;398(6726):417-22
10201371
Gastroenterology. 2008 Sep;135(3):882-8
18514072